These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 8956629

  • 1. Confounding by indication and channeling over time: the risks of beta 2-agonists.
    Blais L, Ernst P, Suissa S.
    Am J Epidemiol; 1996 Dec 15; 144(12):1161-9. PubMed ID: 8956629
    [Abstract] [Full Text] [Related]

  • 2. Re: "Confounding by indication and channeling over time: the risks of beta2-agonists".
    Pearce N, Beasley R, Crane J, Burgess C.
    Am J Epidemiol; 1997 Nov 15; 146(10):885-7. PubMed ID: 9384211
    [No Abstract] [Full Text] [Related]

  • 3. Confounding by severity does not explain the association between fenoterol and asthma death.
    Beasley R, Burgess C, Pearce N, Woodman K, Crane J.
    Clin Exp Allergy; 1994 Jul 15; 24(7):660-8. PubMed ID: 7953948
    [Abstract] [Full Text] [Related]

  • 4. A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists.
    Suissa S, Ernst P, Boivin JF, Horwitz RI, Habbick B, Cockroft D, Blais L, McNutt M, Buist AS, Spitzer WO.
    Am J Respir Crit Care Med; 1994 Mar 15; 149(3 Pt 1):604-10. PubMed ID: 8118625
    [Abstract] [Full Text] [Related]

  • 5. Recent trends in the use of inhaled beta 2-adrenergic agonists and inhaled corticosteroids in Saskatchewan.
    Habbick B, Baker MJ, McNutt M, Cockcroft DW.
    CMAJ; 1995 Nov 15; 153(10):1437-43. PubMed ID: 7585370
    [Abstract] [Full Text] [Related]

  • 6. Risk of severe life threatening asthma and beta agonist type: an example of confounding by severity.
    Garrett JE, Lanes SF, Kolbe J, Rea HH.
    Thorax; 1996 Nov 15; 51(11):1093-9. PubMed ID: 8958891
    [Abstract] [Full Text] [Related]

  • 7. [Long-term effects of inhaled beta 2-agonists on bronchial hyperresponsiveness in asthmatics].
    Ogawa C, Sano Y.
    Nihon Rinsho; 1996 Nov 15; 54(11):3081-6. PubMed ID: 8950959
    [Abstract] [Full Text] [Related]

  • 8. The use of beta-agonists and the risk of death and near death from asthma.
    Spitzer WO, Suissa S, Ernst P, Horwitz RI, Habbick B, Cockcroft D, Boivin JF, McNutt M, Buist AS, Rebuck AS.
    N Engl J Med; 1992 Feb 20; 326(8):501-6. PubMed ID: 1346340
    [Abstract] [Full Text] [Related]

  • 9. Adverse effects of beta-agonists: are they clinically relevant?
    Abramson MJ, Walters J, Walters EH.
    Am J Respir Med; 2003 Feb 20; 2(4):287-97. PubMed ID: 14719995
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and side effects of beta 2-agonists by inhaled route in acute asthma in children: comparison of salbutamol, terbutaline, and fenoterol.
    Scalabrin DM, Solé D, Naspitz CK.
    J Asthma; 1996 Feb 20; 33(6):407-15. PubMed ID: 8968295
    [Abstract] [Full Text] [Related]

  • 11. International trends in sales of inhaled fenoterol, all inhaled beta-agonists, and asthma mortality, 1970-1992.
    Lanes SF, Birmann B, Raiford D, Walker AM.
    J Clin Epidemiol; 1997 Mar 20; 50(3):321-8. PubMed ID: 9120532
    [Abstract] [Full Text] [Related]

  • 12. Case-control study of salmeterol and near-fatal attacks of asthma.
    Williams C, Crossland L, Finnerty J, Crane J, Holgate S, Pearce N, Beasley R.
    Thorax; 1998 Jan 20; 53(1):7-13. PubMed ID: 9577515
    [Abstract] [Full Text] [Related]

  • 13. Clinical complexity and epidemiologic uncertainty in case-control research. Fenoterol and asthma management.
    Horwitz RI, Spitzer W, Buist S, Cockcroft D, Ernst P, Habbick B, Hemmelgarn B, McNutt M, Rebuck AS, Suissa S.
    Chest; 1991 Dec 20; 100(6):1586-91. PubMed ID: 1959400
    [Abstract] [Full Text] [Related]

  • 14. The severity of asthma in relation to beta agonist prescribing.
    Garrett JE, Turner P.
    N Z Med J; 1991 Feb 13; 104(905):39-40. PubMed ID: 1671713
    [Abstract] [Full Text] [Related]

  • 15. A comparison of the extent and duration of hypokalaemia following three nebulized beta 2-adrenoceptor agonists.
    Burgess CD, Flatt A, Siebers R, Crane J, Beasley R, Purdie G.
    Eur J Clin Pharmacol; 1989 Feb 13; 36(4):415-7. PubMed ID: 2567672
    [Abstract] [Full Text] [Related]

  • 16. Dose-effect relationship of the beta-agonists fenoterol and salbutamol in patients with asthma.
    Newhouse MT, Dolovich MB, Kazim F.
    Chest; 1994 Jun 13; 105(6):1738-42. PubMed ID: 8205869
    [Abstract] [Full Text] [Related]

  • 17. Rise and fall of asthma-related mortality in Italy and sales of beta2-agonists, 1980-1994.
    Romano F, Recchia G, Staniscia T, Bonitatibus A, Villa M, Nicolosi A, De Carli G, Mannino S.
    Eur J Epidemiol; 2000 Jun 13; 16(9):783-7. PubMed ID: 11297218
    [Abstract] [Full Text] [Related]

  • 18. Optical illusions from visual data analysis: example of the New Zealand asthma mortality epidemic.
    Suissa S, Ernst P.
    J Clin Epidemiol; 1997 Oct 13; 50(10):1079-88. PubMed ID: 9368515
    [Abstract] [Full Text] [Related]

  • 19. The pulmonary and extrapulmonary effects of inhaled beta-agonists in patients with asthma.
    Windom HH, Burgess CD, Siebers RW, Purdie G, Pearce N, Crane J, Beasley R.
    Clin Pharmacol Ther; 1990 Sep 13; 48(3):296-301. PubMed ID: 1976051
    [Abstract] [Full Text] [Related]

  • 20. The beta 2-agonist controversy. Observations, explanations and relationship to asthma epidemiology.
    Sears MR, Taylor DR.
    Drug Saf; 1994 Oct 13; 11(4):259-83. PubMed ID: 7848546
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.